| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Etoxybamide's mechanism of action is not fully characterized in the available literature. As a sedative and hypnotic, it is likely to act on the central nervous system. Related benzamide derivatives have been shown to act as 5-HT2B receptor antagonists or COX inhibitors. However, the specific molecular target of etoxybamide remains to be definitively established.
|
|---|---|
| ln Vitro |
In vitro studies of etoxybamide are limited. Related compounds (ethoxybenzamides) have been shown to induce melanin synthesis via CREB phosphorylation and to inhibit lipoxygenase or COX. However, specific in vitro activity data for etoxybamide itself are not well-documented.
|
| ln Vivo |
Etoxybamide is not widely used as a therapeutic agent. It has been studied as a sedative and hypnotic drug candidate, but its clinical development status is unclear. It is primarily a research compound used to study sedation and hypnosis.
|
| Enzyme Assay |
Non-cellular receptor binding assays for etoxybamide are not well-documented. As a sedative, its potential targets could include GABA receptors, but specific assays have not been widely published. Standard radioligand binding displacement studies could be employed to screen for activity at various CNS targets.
|
| Cell Assay |
In vitro cellular assays for etoxybamide are not well-documented. Cell-based assays could be used to assess its effects on neuronal excitability or receptor signaling, but specific protocols are not widely available. Its sedative effects are typically assessed in vivo using behavioral models.
|
| Animal Protocol |
In vivo animal experiments with etoxybamide are conducted in rodent models to assess its sedative and hypnotic effects. Animals are treated with etoxybamide via oral or intraperitoneal administration, and behavioral assays such as the open field test, locomotor activity, and the loss of righting reflex are used to evaluate sedation and hypnosis.
|
| ADME/Pharmacokinetics |
Etoxybamide has a molecular weight of 147.17 and a molecular formula of C₉H₉NO₂. It is a solid powder with a purity of ≥98%. The compound is typically stored at room temperature in a dry, dark place. It is soluble in organic solvents and is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Etoxybamide is a research compound for laboratory use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin, eye, and respiratory irritation. Appropriate personal protective equipment should be used.
|
| Additional Infomation |
Drug Indication
Sedation Etoxybamide (CAS 66857-17-8) is a sedative and hypnotic agent. Its exact mechanism of action is not fully characterized. It has been studied as a drug candidate for sedation and serves as a research tool for studying central nervous system depressants. |
| Molecular Formula |
C6H13NO3
|
|---|---|
| Molecular Weight |
147.17232
|
| Exact Mass |
147.09
|
| CAS # |
66857-17-8
|
| PubChem CID |
522232
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
95
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CC(=O)NCCO)CO
|
| InChi Key |
MFHPPMMWHSHDSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13NO3/c8-4-1-2-6(10)7-3-5-9/h8-9H,1-5H2,(H,7,10)
|
| Chemical Name |
4-hydroxy-N-(2-hydroxyethyl)butanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7949 mL | 33.9743 mL | 67.9486 mL | |
| 5 mM | 1.3590 mL | 6.7949 mL | 13.5897 mL | |
| 10 mM | 0.6795 mL | 3.3974 mL | 6.7949 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
